Treatment of epithelioid sarcoma at the Royal Marsden Hospital by Judson, I & Fisher, C
Sarcoma, September/December 2003, VOL. 7, NO. 3/4, 149–152
ORIGINAL ARTICLE
Treatment of epithelioid sarcoma at the Royal Marsden Hospital
L. LIVI1, N. SHAH2, F. PAIAR1, C. FISHER3, I. JUDSON3, E. MOSKOVIC3,
M. THOMAS3 & C. HARMER3
1Radiotherapy Department, Florence University, Florence, Italy, 2Mount Vernon Cancer Centre, Northwood, HA6 2RN, UK,
3Sarcoma Unit, Royal Marsden Hospital, Fulham Road, SW3 6JJ, UK
Abstract
Purpose: The aim of this study was to assess treatment and outcome with respect to clinical and pathological features.
Patients and methods: Thirty-nine patients were identified (range 7–66 years, mean 23). Initial treatment comprised local
excision in 11 patients and wide excision in 14. Post-operative external beam radiotherapy was prescribed in 22 patients
with a total dose of 60Gy, delivered in two phases.
Results: The cause-specific survival for the entire group was 79, 63, 56 and 45% at 1, 3, 5 and 10 years, respectively. A distal
limb location was associated with a better prognosis than proximal limb location (P¼ 0.04).
Conclusions: Our data favour treatment with wide functional excision followed by radical dose radiotherapy in attempt to
minimize risk of local recurrence, especially when primary tumours are bigger than 3 cm. Our data also suggest the same
treatment for local recurrence, when technically possible, to avoid amputation.
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Introduction
Epithelioid sarcoma (ES) is a rare subtype of soft
tissue sarcoma (STS) first described under its
current designation in 1970.1 It is a high grade
tumour which shows both epithelial and mesenchy-
mal differentiation.2,3
ES is likely to be confused with a variety of benign
and malignant conditions, especially a granuloma-
tous process,4 synovial sarcoma,5–7 or an ulcerating
squamous cell carcinoma.4
The peak incidence is in young adults, being rare
in children and in old age. Male patients outnumber
females.8 Principal sites of involvement are the
fingers, hands and forearm; it is the most common
soft tissue sarcoma to involve the hand and wrist. ES
may arise in either the sub-cutis or deeper tissues.
When located in sub-cutis, it usually presents as a
firm nodule that may be solitary or multiple. Deep-
seated lesions are usually firmly attached to tendons
or tendon sheaths. Because many lesions are multi-
nodular, determination of their exact size may be
difficult.9
Multiple recurrences, often the result of marginal
resection, are a characteristic feature of this tumour.
The most common sites of metastases are regional
lymph nodes and lung, less frequently central
nervous system and soft tissue especially over the
scalp.
Prognostic factors include gender, size, depth of
the tumour and the presence of metastases. Accurate
information on survival and prognostic features is
difficult to ascertain in this subtype of STS. The
reason for this is the rarity of the disease.
Assessment and comparison of the efficacy of
treatment is exceedingly difficult to judge from the
literature, as reported series are small and treatment
poorly described. The aim of this study was to assess
treatment and outcome with respect to the clinical
and pathological features.
Methods
A retrospective review was undertaken of the Royal
Marsden Hospital Sarcoma Unit database from
1978–2001 which contains 2733 patients registered
with STS. Forty-nine patients were identified with
ES, but 10 had diagnostic uncertainty and have
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been excluded from further analysis. All cases had
their original histopathology reviewed. Presentation,
treatment, outcome and follow-up were documented
in August 2001.
Thirty-nine patients were identified with a median
follow-up of 82 months (range 2 months to 22 years).
The mean age was 23 years (range 7–66 years)
as shown in Table 1, with a male to female ratio
of 2.9:1.
The site distribution of the primary lesions is
shown in Table 2. Original tumour dimensions
were documented in 24 patients only from clinical
evaluation, radiograph or pathological reports. Initial
treatment comprised incomplete excision in four,
local excision in 11, wide excision in 14, radical
surgery (amputation) in eight and biopsy only in
two patients. No one patient underwent regional
lymph node dissection.
Radical adjuvant post-operative external beam
radiotherapy was prescribed in 22 patients, with a
dose range from 39.6Gy in six fractions over 6 weeks
to 60Gy in 30 fractions over 6 weeks. A single-phase
generously proportioned volume was used in 10
patients. A two-phase volume comprising the whole
compartment followed by a boost to the tumour
bed was planned for the other 12: nine received
50Gy in 25 fractions plus a boost of 10Gy in five
fractions over a total of 6 weeks, one received 40Gy
in 20 fractions plus a boost of 20Gy in 10 fractions,
and two received 48Gy in 24 fractions plus a boost
of 12Gy in six fractions.
Adjuvant chemotherapy was prescribed in only
one patient comprising vincristine, cyclophos-
phamide and doxorubicin.
Statistical analysis
The disease-specific and overall survivals were
analysed using the Kaplan–Meier method (Statistical
software). The Log-rank test was used to compare
survival curves. Univariate was performed to assess
the significance of prognostic factors; all tests of
significance were two sided. Overall survival was
defined as the time from diagnosis to death from
any cause. Local disease-free survival was defined
as the time from diagnosis to first local recurrence.
In cases where disease progressed immediately from
presentation, without response to treatment, local
disease-free survival was considered to be zero.
Results
At the time of analysis, 51% of patients (20/39)
were dead and 49% alive (one with metastatic
disease). The cause-specific survival for the entire
group was 79, 63, 56 and 45% at 1, 3, 5 and 10 years,
respectively, as shown in Figure 1.
As prognostic factors for cause-specific survival we
analysed tumour site, tumour size and age of patients
at presentation.
Distal limb location was associated with a better
prognosis than proximal limb location (P¼ 0.04
on univariate analysis): at time of analysis 58% of
patients with distal limb tumour were alive in
contrast to only 20% who had presented with a
proximal limb tumour. Patients with trunk location
(2/22), vaginal involvement (1/22), regional lymph
node involvement (3/22), and incompletely resected
bulky disease (1/22) developed distant metastases
but, apart from the patients who never were local
disease free, the three with positive nodes died
without evidence of local recurrence.
Age at presentation did not achieve statistical
significance; however, a trend was observed, with
lower age conferring a better survival. At 3 years
follow-up, 73% of patients aged less than 30 years
were alive, in contrast to 48 and 33% for those aged
30–50 years and over 50, respectively.
Similarly a trend was observed for size of primary
tumour. We documented 100% mortality for
tumours larger than 6 cm at presentation in contrast






























Fig. 1. The cause-specific survival was 79, 63, 56 and 45% at
1, 3, 5 and 10 years, respectively.
Table 2. Site distribution of primary tumour
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Twelve patients (30%) developed local recurrence
(LR) as the first site of failure. The actuarial 5-year
LR rate was 39%. Nine out of 12 underwent surgery
only for LR and developed further local recurrence
(six of whom with LR developed metastatic disease
in spite of further surgery and died).
Six of the 12 patients with LR were successfully
salvaged. Two underwent primary surgery only, with
several local recurrences treated by surgery and
eventual amputation (one patient continues to
describe phantom limb pain). Three of the six
underwent primary surgery only, with surgery plus
adjuvant radiotherapy (50Gy in 25 fractionsþ phase
II 10Gy in five fractions) for local recurrence (one
subsequently required amputation for further LR).
The sixth was treated by primary surgery, with
surgery only for LR and died 13 years later from lung
cancer but no evidence of sarcoma.
At the time of analysis, 13 patients (33%) had
developed distant tumour as the first site of failure
after initial therapy, at a median time of 16 months
(range 4–79 months). The actuarial 5-year metastasis
rate was 33%. The median post-metastasis survival
was only 10 months.
Eight patients received palliative chemotherapy
only, and five a combination of radiotherapy and
chemotherapy. None were considered suitable for
metastasesctomy because either the tumour-free
interval was short or metastases were too numerous
and bilateral.
Discussion
Epithelioid sarcoma is a rare variant of STS with
characteristic features both clinically and on histo-
pathology. In most series it comprises less than 1%
all of STS.10 There is still no consensus as to the
exact nature and cell type of ES.
ES has a propensity to occur in young male adults
and tends to favour limb locations, especially the
distal upper limb.11,12
Precise information on survival and prognostic
features is difficult to ascertain in this rare subtype of
STS. Bos et al.13 report 70% survival at 5 years, with
other studies quoting a range between 58 and 100%.
In our experience, cause-specific survival was 63, 56
and 45% at 3, 5 and 10 years, respectively; the first
local recurrence is likely to occur within the first
3 years. However, late relapse may occur: one patient
developed first local recurrence after 8 years from
the end of treatment and two patients developed
further local recurrence after 7 years from end of
second treatment.14,15
Metastatic disease generally occurred within 2
years after the end of treatment. When local
recurrence had previously occurred, metastatic dis-
ease followed within 2 years.
In previous series, adverse prognosis has been
correlated with size of the primary tumour, proximal
limb and axial tumour site, depth of tumour in
relation to deep fascia, and local recurrence or lymph
node involvement.16,17
In our series, univariate analysis confirms a better
prognosis for distal limb tumours (P¼ 0.04). There
is no statistical significance for the other parameters,
but this is likely to be a reflection of the small number
of patients evaluated.
Although our results do not demonstrate statistical
significance, there is a definite trend for improved
disease-free survival and overall survival for surgery
with clear excision margins followed by adjuvant
radiotherapy. In our series, 55% of patients treated
with local excision had local recurrence in contrast
with 35% of patients treated with wide excision. For
overall survival, mortality rates of 75, 27 and 21%
are noted for patients who underwent incomplete
excision, local excision and wide excision, respec-
tively. Subgroup analysis of tumours more than 3 cm
in size demonstrates mortality rates of 100, 50 and
28% for patients treated with incomplete, local
and wide excision, respectively. This is supported
by Callister et al., who reported the multivariate
analysis of the factor correlating with the overall,
disease-free and metastasis-free survival: the favour-
able prognostic significance of small lesion size.18
Amputation, used either as initial primary treat-
ment or for recurrence, did not confer a survival
advantage, as previously documented.19
For the more common varieties of STS, adjuvant
radical dose radiotherapy encompassing the entire
anatomical compartment improves local control and
survival. For ES, this is supported by Suit et al.20,21
and Shimm & Suit22 where a low local recurrence
rate is noted.
Our study fails to demonstrate a significant
advantage for adjuvant radiotherapy, but this may
be confounded by the disparity of tumour sizes. The
incidence of LR was similar (30%) for patients
treated with adjuvant radiotherapy or surgery only;
however, in the former group all tumours were
bigger than 3 cm compared to the latter group
where all tumours were smaller than 3 cm.
Talbert and Kinsella also confirmed improved
outcome using adjuvant radiotherapy both after
primary surgery and after surgery for local
recurrence.23–27
This type of radiotherapy treatment was effective
as adjuvant treatment after primary surgery and as
second treatment after surgery for local recurrence.
Significant late sequelae and abnormal limb
function were not observed in our series. This is
supported by Okunieff et al.,28 who reported that
patients with local control after combined modality
treatment of the hand and wrist, had less than a
25% impairment in limb function and had no pain
or oedema.
The frequency of recurrence within the high-dose
volume (six patients treated with a total dose of
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60Gy, four of whom received 50Gyþ 10Gy) may
suggest the need for use of a higher total dose of
radiotherapy.19
Considering our median time for distant meta-
stases and the possibility of LR also after several
years, we recommended a follow-up every 3 months,
combining clinical examination and chest X-ray
for the first 3 year; then twice a year for another
2 years and then annually.
Conclusions
Our series is too small to draw any definitive
conclusion and the results must be interpreted with
caution. The dominant prognostic factor was the
site of the primary tumour, with best prognosis for
distal limb location. Our data favour treatment
with wide functional excision, followed by radical
dose radiotherapy in an attempt to minimize risk of
local recurrence, especially when primary tumours
are bigger than 3 cm. We also recommend the
same treatment for local recurrence, when techni-
cally possible, to avoid amputation which should be
reserved for inoperable recurrent disease following
previous radiotherapy, in the absence of distant
spread.
When metastatic disease develops, prognosis is
poor, with a median survival of only 10 months.
Chemotherapy has not been proven to prolong
survival, but novel agents and scheduling are under
investigation. We recommend earlier diagnosis,
dependent on increased clinical and pathological
awareness, as diagnosis is typically delayed. Finally,
we recommend earlier referral to a multidisciplinary
specialist team within the cancer network.
References
1. Enzinger F. Epitheloid sarcoma. A sarcoma simulating
a granuloma or a carcinoma. Cancer 1970; 26: 1029–41.
2. Fisher C. Epithelioid sarcoma: the spectrum of ultra-
structural differentiation in seven immunohistochemi-
cally defined cases. Hum Pathol 1988; 19: 265–75.
3. Smith ME, Brown JI, Fisher C. Epithelioid sarcoma:
presence of vascular-endothelial cadherin and lack of
epithelial cadherin. Histopathology 1998; 33: 425–31.
4. Enzinger, Weiss, eds. Malignant soft tissue sarcoma of
uncertain types. In: Soft Tissue Tumours, Chapter 37. St.
Louis, MO: Mosby, 2001; 1523–34.
5. Fletcher CDM, Beham A, Bekir S, et al. Epithelioid
angiosarcoma of the deep soft tissue: a distinctive tumor
readily mistaken for an epithelioid neoplasm. Am J Surg
Pathol 1991; 15: 915.
6. Miettinen M, Letho VP, Vartio T, et al. Epithelioid
sarcoma: an immonohistochemical analysis of 112
classical and variant cases and discussion of the
differential diagnosis. Hum Pathol 1999; 30: 934.
7. Hazelbag HM, Mooi WJ, Fleurn GJ, et al. Gene-
specific keratin profile of epithelioid soft-tissue sar-
coma: an immunohistochemical, study on synovial
sarcoma and epithelioid sarcoma. Appl Immunohisto-
chem 1996; 4: 176.
8. Chase DR, Enzinger FM. Epithelioid sarcoma.
Diagnosis, prognostic indicators, and treatment. Am
J Surg Pathol 1985; 9: 241–63.
9. Enzinger, Weiss, eds. Malignant soft tissue sarcoma of
uncertain types. In: Soft Tissue Tumours, Chapter 37.
St. Louis, MO: Mosby, 2001; 1521–2.
10. Ross HM, Lewis JJ, Woodruff JM, Brennan MF.
Epithelioid sarcoma: clinical behavior and prognostic
factors of survival. Ann Surg Oncol 1997; 4: 491–5.
11. Spillane AJ, Thomas JM, Fisher C. Epithelioid sar-
coma: the clinicopathological complexities of this rare
soft tissue sarcoma. Ann Surg Oncol 2000; 7: 218–25.
12. Enzinger, F. Malignant soft tissue sarcoma of uncer-
tain types. In: Enzinger F, ed. Soft Tissue Tumours,
Chapter 38. St. Louis, MO: Mosby, 1995.
13. Bos GD, et al. Epithelioid sarcoma. An analysis of fifty-
one cases. J Bone Joint Surg Am 1988; 70: 862–70.
14. Cleator SJ, Cottrill C, Harmer C. Pattern of local
recurrence after conservative surgery and radiotherapy
for soft tissue sarcoma. Sarcoma 2001; 5: 83–8.
15. Evans HL, Baer SC. Epithelioid sarcoma: a clinico-
pathologic and prognostic study of 26 cases. Semin
Diagn Pathol 1993; 10: 286–91.
16. Fong Y, Coit DG, Woodruff JM, Brennan MF.
Lymph node metastasis from soft tissue sarcoma in
adults. Analysis of data from a prospective database of
1772 sarcoma patients. Ann Surg 1993; 217: 72–7.
17. Prat J, Woodruff JM, Marcove RC. Epithelioid
sarcoma: an analysis of 22 cases indicating the prog-
nostic significance of vascular invasion and regional
lymph node metastasis. Cancer 1978; 41: 1472–87.
18. Callister MD, Ballo MT, Pisters PWT, et al. Epithe-
lioid Sarcoma:results of conservative surgery and
radiotherapy. Int J Radiat Oncol Biol Phys 2001;
51(2): 384–91.
19. Hasegawa T, et al. Proximal-type epithelioid sarcoma:
a clinicopathologic study of 20 cases. Mod Pathol
2001; 14: 655–63.
20. Suit HD, Russell WO, Martin RG. Management of
patients with sarcoma of soft tissue in an extremity.
Cancer 1973; 31: 1247–55.
21. Suit HD, Russell WO, Martin RG. Sarcoma of soft
tissue: clinical and histopathologic parameters and
response to treatment. Cancer 1975; 35: 1478–83.
22. Shimm DS, Suit HD. Radiation therapy of epithelioid
sarcoma. Cancer 1983; 52: 1022–5.
23. Jyothrmayi R, Sittamplam Y, Harmer C. Soft tissue
sarcoma of the hand or foot: conservative surgery
and radiotherapy. Sarcoma 1999; 3: 17–24.
24. Harmer C, Bidmead M. Three-dimensional planning
and conformal radiotherapy. Cancer Treat Res 1997;
91: 129–41.
25. Whitworth PW, Pollock RE, Mansfield PF, Couture J,
Romsdahl MM. Extremity epithelioid sarcoma.
Amputation vs local resection. Arch Surg 1991; 126:
1485–9.
26. Talbert ML, Zagars GK, Sherman NE, Romsdahl
MM. Conservative surgery and radiation therapy
for soft tissue sarcoma of the wrist, hand, ankle, and
foot. Cancer 1990; 66: 2482–91.
27. Kinsella TJ, Loeffler JS, Fraass BA, Tepper J. Extrem-
ity preservation by combined modality therapy in
sarcomas of the hand and foot: an analysis of local
control, disease free survival and functional result. Int
J Radiat Oncol Biol Phys 1983; 9: 1115–9.
28. Okunieff P, Suit HD, Proppe KH. Extremity pres-
ervation by combined modality treatment of sarcomas
of the hand and wrist. Int J Radiat Oncol Biol Phys
1986; 12: 1923–9.
152 L. Livi et al.
